Skip to main
AKTS

AKTS Stock Forecast & Price Target

AKTS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aktis Oncology is positioned to potentially succeed in a growing market as they focus on expanding the potential of targeted radiopharmaceuticals for solid tumor cancers. With a strong collaboration agreement and promising pipeline, the company has the resources and expertise to drive value for shareholders and patients alike.

Bears say

Aktis Oncology is facing potential financial challenges with their current portfolio and pipeline. Although they have promising results with their Nectin-4 targeting drug, [225Ac]Ac-AKY-1189, as well as partnerships and designations for their other drugs, the company may struggle to fund their research and development efforts. This could hinder their ability to bring products to market and generate revenue, ultimately affecting their stock price.

AKTS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aktis Oncology Inc (AKTS) Forecast

Analysts have given AKTS a Buy based on their latest research and market trends.

According to 7 analysts, AKTS has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aktis Oncology Inc (AKTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.